http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2006006674-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 |
| filingDate | 2005-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2006006674-A1 |
| titleOfInvention | Transmucosal administration agent containing PTH |
| abstract | A method for suppressing symptoms such as nausea upon administration of PTH and a pharmaceutical composition capable of suppressing the symptoms. To increase bone mass or bone density, and to suppress an increase in the risk of developing one or more symptoms selected from the group consisting of foot cramps, nausea, headache, and dizziness associated with hPTH administration A pharmaceutical composition for transmucosal administration containing hPTH or a derivative thereof, wherein both the bone forming action and the bone resorption action of PTH are retained. |
| priorityDate | 2004-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 910.